Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q4 FY22 results · Jan–Mar 2022
Lincoln Pharmaceuticals reported revenue from operations of ₹102.59 crore and net profit of ₹11.02 crore for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 102.59 | — | — | — | — |
| Other income | 1.89 | — | — | — | — |
| Total income | 104.48 | — | — | — | — |
| Profit before tax | 16.77 | — | — | — | — |
| Net profit for the period | 11.02 | — | — | — | — |
| EPS, basic (₹) | 5.50 | — | — | — | — |
| Net margin (%) | 10.7 | — | — |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 102.54 | 77.54 | +32.2% | 119.88 | −14.5% |
| Other income | 1.89 | 2.51 | −24.6% | 2.64 | −28.3% |
| Total income | 104.43 | 80.05 | +30.5% | 122.52 | −14.8% |
| Profit before tax | 16.76 | 14.79 | +13.3% | 23.60 | −29.0% |
| Net profit for the period | 11.02 | 11.85 | −7.0% | 17.60 | −37.4% |
| EPS, basic (₹) | 5.50 | 5.92 | −7.1% | 8.79 | −37.4% |
| Net margin (%) | 10.8 | 15.3 | 14.7 |
Consolidated
- Filed with BSE
- 20 Jun 2022, 16:58 IST
- Board meeting
- 19 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 20 Jun 2022, 16:58 IST
- Board meeting
- 19 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE